Target Name: MIR3194
NCBI ID: G100422889
Review Report on MIR3194 Target / Biomarker Content of Review Report on MIR3194 Target / Biomarker
MIR3194
Other Name(s): MicroRNA 3194 | microRNA 3194 | hsa-miR-3194-5p | mir-3194 | hsa-mir-3194 | hsa-miR-3194-3p

MIR3194: A Promising Drug Target and Biomarker

Gene expression plays a critical role in various biological processes, including development, disease progression, and drug response. Identifying specific genes that act as drug targets or biomarkers has become a major focus in biomedical research. One such gene, MIR3194, has emerged as a promising candidate due to its involvement in several diseases and potential therapeutic applications. In this article, we explore the significance of MIR3194 as a drug target and biomarker, shedding light on its potential applications in precision medicine.

The World of MicroRNAs

MicroRNAs (miRNAs) are small non-coding RNA molecules that play a pivotal role in post-transcriptional gene regulation. By binding to the messenger RNA (mRNA) of target genes, miRNAs control the expression of these genes, either by inhibiting translation or by promoting mRNA degradation. As a result, miRNAs have the power to fine-tune gene expression and shape cellular processes.

MIR3194: A Unique MicroRNA

Among the myriad of miRNAs discovered, MIR3194 stands out as a unique player in the cellular orchestra. This particular miRNA has been found to be dysregulated in multiple diseases, suggesting its potential as a valuable drug target or biomarker.

MIR3194 in Cancer

Cancer is a complex disease characterized by abnormal cell growth and proliferation. Mounting evidence indicates that MIR3194 can modulate various signaling pathways that are crucial for cancer development and progression. For example, in hepatocellular carcinoma (HCC), downregulation of MIR3194 has been associated with increased tumor aggressiveness and poor prognosis. Conversely, restoration of MIR3194 levels suppresses tumor growth, pointing towards its therapeutic potential.

Similarly, in breast cancer, MIR3194 has been shown to inhibit cancer cells' ability to invade and metastasize. This miRNA achieves its anti-cancer effects by suppressing key genes involved in epithelial-mesenchymal transition and angiogenesis. As a result, targeting MIR3194 could potentially serve as a novel therapeutic approach for combating breast cancer.

MIR3194 in Cardiovascular Diseases

Cardiovascular diseases (CVDs) remain a leading cause of mortality worldwide. Interestingly, recent studies have highlighted the role of MIR3194 in the development and progression of CVDs. In heart failure patients, levels of MIR3194 have been found to be significantly reduced, suggesting its potential as a diagnostic biomarker. Moreover, experimental studies have demonstrated that increasing MIR3194 expression in cardiac cells can attenuate pathological remodeling and improve cardiac function. These findings open up new avenues for the development of targeted therapies for CVDs.

MIR3194 in Neurological Disorders

Neurological disorders, such as Alzheimer's disease and Parkinson's disease, present one of the most challenging fields in medicine. Interestingly, emerging evidence suggests that miRNAs, including MIR3194, play a crucial role in the pathogenesis of these disorders. Dysregulation of MIR3194 has been observed in the brains of Alzheimer's disease patients, indicating its potential as a diagnostic biomarker. Additionally, MIR3194 has been found to regulate key genes involved in neuronal survival and synaptic plasticity, underlining its therapeutic potential in neurodegenerative diseases.

Exploiting MIR3194 as a Drug Target

The dysregulation of MIR3194 in various diseases opens up new avenues for therapeutic interventions. Approaches that specifically modulate MIR3194 expression, such as miRNA mimics or inhibitors, could potentially restore its levels to normal and restore cellular homeostasis. Furthermore, as MIR3194 seems to exert its effects by targeting multiple genes within disease-associated signaling pathways, it holds the potential to overcome the limitations of single-target therapies.

MIR3194 as a Biomarker

In addition to its role as a drug target, MIR3194 also holds promise as a biomarker in disease diagnosis and prognosis. Its dysregulation in various diseases, including cancer, cardiovascular diseases, and neurological disorders, suggests that measuring MIR3194 expression levels may provide valuable information about disease presence, stage, and response to therapy. Moreover, as a non-invasive biomarker, MIR3194 measurement could be easily performed using readily available body fluids, such as blood or cerebrospinal fluid.

The Future of MIR3194 Research

As the understanding of MIR3194 expands, ongoing research is elucidating its precise mechanisms and therapeutic implications. Further investigation is needed to fully harness the potential of MIR3194 as a therapeutic target and biomarker. Additionally, large-scale clinical trials are required to validate its diagnostic and therapeutic utility across different disease contexts.

In conclusion, MIR3194 represents a significant step forward in the quest for precision medicine. Its dysregulation in various diseases underscores its potential as a drug target and biomarker. Exploiting the therapeutic potential of MIR3194 and harnessing its diagnostic capabilities could revolutionize disease management and significantly improve patient outcomes.

Protein Name: MicroRNA 3194

The "MIR3194 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR3194 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR3195 | MIR3196 | MIR3197 | MIR3198-1 | MIR3199-1 | MIR3199-2 | MIR31HG | MIR32 | MIR3200 | MIR3201 | MIR3202-1 | MIR3202-2 | MIR320A | MIR320B1 | MIR320B2 | MIR320C1 | MIR320C2 | MIR320D1 | MIR320D2 | MIR320E | MIR323A | MIR323B | MIR324 | MIR325 | MIR325HG | MIR326 | MIR328 | MIR329-1 | MIR329-2 | MIR330 | MIR331 | MIR335 | MIR337 | MIR338 | MIR339 | MIR33A | MIR33B | MIR340 | MIR342 | MIR345 | MIR346 | MIR34A | MIR34AHG | MIR34B | MIR34C | MIR3529 | MIR3591 | MIR3605 | MIR3606 | MIR3609 | MIR361 | MIR3610 | MIR3611 | MIR3612 | MIR3613 | MIR3614 | MIR3615 | MIR3616 | MIR3617 | MIR3618 | MIR3619 | MIR362 | MIR3620 | MIR3621 | MIR3622A | MIR3622B | MIR363 | MIR3646 | MIR3648-1 | MIR3649 | MIR3650 | MIR3651 | MIR3652 | MIR3654 | MIR3655 | MIR3658 | MIR3659 | MIR365A | MIR365B | MIR3660 | MIR3661 | MIR3662 | MIR3663 | MIR3664 | MIR3665 | MIR3667 | MIR3667HG | MIR3668 | MIR367 | MIR3670-1 | MIR3670-2 | MIR3671 | MIR3672 | MIR3674 | MIR3675 | MIR3677 | MIR3678 | MIR3679 | MIR3680-1 | MIR3680-2